Leronlimab does what Keytruda does so leronlimab does not add efficacy it supplants Keytruda entirely and adds additional benefit. If Merck didn't track PD-1 levels they may try to say a leronlimab/Keytruda combo would be great. Until of course it was exposed that Keytruda adds nothing to the combo. If they did track PD-1 their first response was probably dismay that Keytruda has been supplanted. Their second response should be, what's the cheapest price we can buy this.

Quote:

---

Leronlimab elicits an NKT cell response - promoting tumor cell death , upregulates CD8+ T cells, Inhibits angiogenesis, shuts down cancer reappearing through collagen downregulation, Stops the recruitment of Tregs to tumor sites (Tregs promote tumor immunity), inhibits tumor cell dna repair, inhibits IL-13 a tumor protectant, downregulates IL-4 (IL-4 promotes tumor immunity), upregulates IFN-gamma promoting tumor cell death, downregulates PD-1 -PD-L1's receptor, polarization of macrophages - promoting tumor cell death , downregulates calcium channel signaling, blocks CCL5 shutting down pathways for CTCs.

---